Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 7, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gena Wang Downgraded (BLUE) to Sell and Decreased Target to $4 on, Mar 7th, 2022
Gena Wang of Barclays, Downgraded "bluebird bio, Inc." (BLUE) to Sell and Decreased Target from $13 to $4 on, Mar 7th, 2022.
Gena has made no other calls on BLUE in the last 4 months.
There is 1 other peer that has a rating on BLUE. Out of the 1 peers that are also analyzing BLUE, 0 agree with Gena's Rating of Hold.
This is the rating of the analyst that currently disagrees with Gena
- Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $10 on, Monday, November 8th, 2021
